Endocannabinoid signalling in innate and adaptive immunity

Immunology

Volumn 144, Issue 3, 2015, Pages 352-364

  Chiurchiu, Valerio ^a   Battistini, Luca ^a   Maccarrone, Mauro ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Cell signalling; Endocannabinoids; Immune cells

Indexed keywords

ENDOCANNABINOID;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CELL POPULATION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOREGULATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LIPID METABOLISM; MACROPHAGE; MOLECULARLY TARGETED THERAPY; MONOCYTE; MOUSE MODEL; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 85003550846     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12441     Document Type: Review

References (137)

1. Di Marzo V, Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid:’killing two birds with one stone’. Prostaglandins Leukot Essent Fatty Acids 1995; 53:1-11.
2. Fezza F, Bari M, Florio R, Talamonti E, Feole M, Maccarrone M. Endocannabinoids, related compounds and their metabolic routes. Molecules 2014; 19:17078-106.
3. Devane WA, Hannus L, Breuer A et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258:1946-9.
4. Mechoulam R, Ben-Shabat S, Hanus L et al. Identification of an endogenous 2-mono-glyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50:83-90.
5. Thabuis C, Tissot-Favre D, Bezelgues JB, Martin JC, Cruz-Hernandez C, Dionisi F, Destaillats F. Biological functions and metabolism of oleoylethanolamide. Lipids 2008; 43:887-94.
6. Di Cesare Mannelli L, D’Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C, Calignano A. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-a-mediated mechanism. Mediators Inflamm 2013; 2013:328797.
7. Hansen HS. Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. Exp Neurol 2010; 224:48-55.
8. Gaetani S, Kaye WH, Cuomo V, Piomelli D. Role of endocannabinoids and their analogues in obesity and eating disorders. Eat Weight Disord 2008; 13:e42-6.
9. Oddi S, Fezza F, Pasquariello N, De Simone C, Rapino C, Dainese E, Finazzi-Agro A, Maccarrone M. Evidence for the intracellular accumulation of anandamide in adiposomes. Cell Mol Life Sci 2008; 65:840-50.
10. Oddi S, Fezza F, Pasquariello N et al. Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. Chem Biol 2009; 16:624-32.
11. Kaczocha M, Glaser ST, Chae J, Brown DA, Deutsch DG. Lipid droplets are novel sites of N-acylethanolamine inactivation by fatty acid amide hydrolase-2. J Biol Chem 2010; 285:2796-806.
12. Maccarrone M, Dainese E, Oddi S. Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci 2010; 35:601-8.
13. Ueda N, Tsuboi K, Uyama T. Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J 2013; 9:1874-94.
14. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 2004; 279:5298-305.
15. Sun YX, Tsuboi K, Okamoto Y, Tonai T, Murakami M, Kudo I, Ueda N. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J 2004; 380:749-56.
16. Simon GM, Cravatt BF. Characterization of mice lacking candidate N-acyl ethanol-amine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. Mol BioSyst 2010; 6:1411-8.
17. Liu J, Wang L, Harvey-White J et al. A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA 2006; 103:13345-50.
18. Bisogno T, Howell F, Williams G et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 2003; 163:463-8.
19. Nakane S, Oka S, Arai S, Waku K, Ishima Y, Tokumura A, Sugiura T. 2-Arachido-noyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-sn-glycerol, a cannabinoid receptor ligand, in rat brain. Arch Biochem Biophys 2002; 402:51-8.
20. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005; 74:411-32.
21. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007; 14:1347-56.
22. Marrs WR, Blankman JL, Horne EA et al. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci 2010; 13:951-7.
23. Pertwee RG, Howlett AC, Abood ME et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010; 62:588-631.
24. Basu S, Dittel BN. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 2011; 51:26-38.
25. Van Sickle MD, Duncan M, Kingsley PJ et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310:329-32
26. Onaivi ES, Ishiguro H, Gong JP et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006; 1074:514-36.
27. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 2010; 3:467-79.
28. Patel KD, Davison JS, Pittman QJ, Sharkey KA. Cannabinoid CB2 receptors in health and disease. Curr Med Chem 2010; 17:1393-410.
29. Galve-Roperh I, Chiurchiu V, Dıaz-Alonso J, Bari M, Guzman M, Maccarrone M. Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog Lipid Res 2013; 52:633-50.
30. Di Marzo V, De Petrocellis L. Endocannabinoids as regulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 2010; 17:1430-49.
31. Zygmunt PM, Ermund A, Movahed P et al. Monoacylglycerols activate TRPV1 – a link between phospholipase C and TRPV1. PLoS ONE 2013; 8:e81618.
32. Xia R, Samad TA, Btesh J, Jiang LH, Kays I, Stjernborg L, Dekker N. TRPV1 signaling: mechanistic understanding and therapeutic potential. Curr Top Med Chem 2011; 11:2180-91.
33. Pistis M, Melis M. From surface to nuclear receptors: the endocannabinoid family extends its assets. Curr Med Chem 2010; 17:1450-67.
34. Moriconi A, Cerbara I, Maccarrone M, Topai A. GPR55: current knowledge andfuture perspectives of a purported “Type-3” cannabinoid receptor. Curr Med Chem 2010; 17:1411-29.
35. Centonze D, Battistini L, Maccarrone M. The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des 2008; 14:2370-82.
36. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res 2009; 60:85-92.
37. Tanasescu R, Gran B, Constantinescu CS. The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease. Amino Acids 2013; 45:95-112.
38. Sanchez Lopez AJ, Roman-Vega L, Ramil Tojeiro E, Giuffrida A, Garcıa-Merino A. Regulation of cannabinoid receptor gene expression and endocannabinoid levels in lymphocyte subsets by IFN-b: a longitudinal study in multiple sclerosis patients. Clin Exp Immunol 2014; 179:119-27.
39. McAllister SD, Glass M. CB1 and CB2 receptor-mediated signalling: a focus on endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 2002; 66:161-71.
40. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 1993; 214:173-80.
41. Galiegue S, Mary S, Marchand J et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232:54-61.
42. Lee SF, Newton C, Widen R, Friedman H, Klein TW. Differential expression of cannabinoid CB2 receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. Eur J Pharmacol 2001; 423:235-41.
43. Graham ES, Angel CE, Schwarcz LE, Dunbar PR, Glass M. Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. Int J Immunopathol Pharmacol 2010; 23:25-34.
44. Berdyshev EV, Boichot E, Germain N, Allain N, Anger JP, Lagente V. Influence of fatty acid ethanolamides and D9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 1997; 330:231-40.
45. Eisenstein TK, Meissler JJ, Wilson Q, Gaughan JP, Adler MW. Anandamide and D9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J Neuroimmunol 2007; 189:17-22.
46. Solorzano C, Zhu C, Battista N et al. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A 2009; 106:20966-71.
47. Stefano GB, Bilfinger TV, Rialas CM, Deutsch DG. 2-Arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. Pharmacol Res 2000; 42:317-22.
48. Jorda MA, Verbakel SE, Valk PJ, Vankan-Berkhoudt YV, Maccarrone M, Finazzi-Agro A, Lowenberg B, Delwel R. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 2002; 99:2786-93.
49. Ouyang Y, Hwang SG, Han SH, Kaminski NE. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through downregulation of the nuclear factor of activated T cells. Mol Pharmacol 1998; 53:676-83.
50. Kaplan BL, Ouyang Y, Rockwell CE, Rao GK, Kaminski NE. 2-Arachidonoyl-glycerol suppresses interferon-c production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2. J Leukoc Biol 2005; 77:966-74.
51. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172:2731-8.
52. Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol 2014; 14:392-404.
53. Sun YX, Tsuboi K, Zhao LY, Okamoto Y, Lambert DM, Ueda N. Involvement of N-a-cylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta 2005; 1736:211-20.
54. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005; 95:437-45.
55. Jiang LS, Pu J, Han ZH, Hu LH, He B. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc Res 2009; 81:805-13.
56. Sugamura K, Sugiyama S, Nozaki T et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009; 119:28-36.
57. Chiurchiu V, Lanuti M, Catanzaro G, Fezza F, Rapino C, Maccarrone M. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis 2014; 233:55-63.
58. Di Marzo V, De Petrocellis L, Sepe N, Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem J 1996; 316:977-84.
59. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 1997; 272:3315-23.
60. Chang YH, Lee ST, Lin WW. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem 2001;81:715-23.
61. Zhu C, Solorzano C, Sahar S, Realini N, Fung E, Sassone-Corsi P, Piomelli D. Proin-flammatory stimuli control N-acylphosphatidylethanolamine-specific phospholipase D expression in macrophages. Mol Pharmacol 2011; 79:786-92.
62. Chicca A, Marazzi J, Nicolussi S, Gertsch J. Evidence for bidirectional endocannabinoid transport across cell membranes. J Biol Chem 2012; 287:34660-82.
63. Maccarrone M, Bari M, Battista N, Finazzi-Agro A. Estrogen stimulates arachidonoy-lethanolamide release from human endothelial cells and platelet activation. Blood 2002; 100:4040-8.
64. Cabral GA, Toney DM, Fischer-Stenger K, Harrison MP, Marciano-Cabral F. Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci 1995; 56:2065-72.
65. Ross RA, Brockie HC, Pertwee RG. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur J Pharmacol 2000; 401:121-30.
66. Correa F, Docagne F, Clemente D, Mestre L, Becker C, Guaza C. Anandamide inhibits IL-12p40 production by acting on the promoter repressor element GA-12: possible involvement of the COX-2 metabolite prostamide E2. Biochem J 2008; 409:761-70.
67. Correa F, Hernangomez M, Mestre L, Lorıa F, Spagnolo A, Docagne F, Di Marzo V, Guaza C. Anandamide enhances IL-10 production in activated microglia by targeting CB2 receptors: roles of ERK1/2, JNK, and NF-jB. Glia 2010; 58:135-47.
68. Correa F, Hernangomez-Herrero M, Mestre L, Lorıa F, Docagne F, Guaza C. The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav Immun 2011; 25:736-49.
69. Hernangomez M, Mestre L, Correa FG et al. CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia 2012; 60:1437-50.
70. Shiratsuchi A, Watanabe I, Yoshida H, Nakanishi Y. Involvement of cannabinoid receptor CB2 in dectin-1-mediated macrophage phagocytosis. Immunol Cell Biol 2008; 86:179-84.
71. Redlich S, Ribes S, Schutze S, Czesnik D, Nau R. Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 and Streptococcus pneumoniae R6 by microglial cells. J Neuroimmunol 2012; 244:32-4.
72. Redlich S, Ribes S, Schutze S, Nau R. Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections. J Neuroinflammation 2014; 11:108.
73. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethan-olamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 2003; 23:7767-75.
74. Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners in crime? Immunology 2014; 141:314-27.
75. Gallily R, Breuer A, Mechoulam R. 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-a production in murine macrophages, and in mice. Eur J Pharmacol 2000; 406:R5-7.
76. Lourbopoulos A, Grigoriadis N, Lagoudaki R et al. Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res 2011; 1390:126-41.
77. Kishimoto S, Kobayashi Y, Oka S, Gokoh M, Waku K, Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J Biochem 2004; 135:517-24.ª 2015 John Wiley & Sons Ltd, Immunology, 144, 352-364
78. Kishimoto S, Gokoh M, Oka S, Muramatsu M, Kajiwara T, Waku K, Sugiura T. 2-Arachidonoylglycerol induces the migration of HL-60 cells differentiated into macro-phage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J Biol Chem 2003; 278:24469-75.
79. Gokoh M, Kishimoto S, Oka S, Metani Y, Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. FEBS Lett 2005; 579:6473-8.
80. Gokoh M, Kishimoto S, Oka S, Sugiura T. 2-Arachidonoylglycerol enhances the phagocytosis of opsonized zymosan by HL-60 cells differentiated into macrophage-like cells. Biol Pharm Bull 2007; 30:1199-205.
81. Alhouayek M, Muccioli GG. COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci 2014; 35:284-92.
82. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31:563-604.
83. Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di Marzo V. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem 2002; 269:3771-8.
84. Maestroni GJ. The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemo-attractant for dendritic cells and adjuvant for Th1 response to a soluble protein. FASEB J 2004; 18:1914-6.
85. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-jB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 2004; 173:2373-82.
86. Karmaus PW, Chen W, Crawford RB, Harkema JR, Kaplan BL, Kaminski NE. Deletion of cannabinoid receptors 1 and 2 exacerbates APC function to increase inflammation and cellular immunity during influenza infection. J Leukoc Biol 2011; 90:983-95.
87. Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, Sakai M, Costa-Pinto FA, Palermo-Neto J. Anandamide prior to sensitization increases cell-mediated immunity in mice. Int Immunopharmacol 2010; 10:431-9.
88. Chiurchiu V, Cencioni MT, Bisicchia E et al. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann Neurol 2013; 73:626-36.
89. Mocsai A. Diverse novel functions of neutrophils in immunity, inflammation, and beyond. J Exp Med 2013; 210:1283-99.
90. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9.
91. Sugiura T, Oka S, Gokoh M, Kishimoto S, Waku K. New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. J Pharmacol Sci 2004; 96:367-75.
92. Kishimoto S, Muramatsu M, Gokoh M, Oka S, Waku K, Sugiura T. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem 2005; 137:217-23.
93. Chiurchiu V, Lanuti M, De Bardi M, Battistini L, Maccarrone M. The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells. Int Immunol 2014; pii: dxu097.
94. McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol 2008; 73:441-50.
95. Kaufmann I, Schelling G, Eisner C et al. Anandamide and neutrophil function in patients with fibromyalgia. Psychoneuroendocrinology 2008; 33:676-85.
96. Kraft B, Wintersberger W, Kress HG. Cannabinoid receptor-independent suppressionof the superoxide generation of human neutrophils (PMN) by CP55 940, but not by anandamide. Life Sci 2004; 75:969-77.
97. Kraft B, Kress HG. Indirect CB2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoids. J Pharmacol Exp Ther 2005; 315:641-7.
98. Montecucco F, Di Marzo V, da Silva RF et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012; 33:846-56.
99. Chouinard F, Lefebvre JS, Navarro P et al. The endocannabinoid 2-arachidonoyl-glyc-erol activates human neutrophils: critical role of its hydrolysis and de novo leukotriene B4 biosynthesis. J Immunol 2011; 186:3188-96.
100. Chouinard F, Turcotte C, Guan X et al. 2-Arachidonoyl-glycerol- and arachidonic acid-stimulated neutrophils release antimicrobial effectors against E. coli, S. aureus, HSV-1, and RSV. J Leukoc Biol 2013; 93:267-76.
101. Kurihara R, Tohyama Y, Matsusaka S, Naruse H, Kinoshita E, Tsujioka T, Katsumata Y, Yamamura H. Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. J Biol Chem 2006; 281:12908-18.
102. Voehringer D. Protective and pathological roles of mast cells and basophils. Nat Rev Immunol 2013; 13:362-75.
103. Jacobsen EA, Helmers RA, Lee JJ, Lee NA. The expanding role(s) of eosinophils in health and disease. Blood 2012; 120:3882-90.
104. Oka S, Ikeda S, Kishimoto S, Gokoh M, Yanagimoto S, Waku K, Sugiura T. 2-Arachi-donoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. J Leukoc Biol 2004; 76:1002-9.
105. Kishimoto S, Oka S, Gokoh M, Sugiura T. Chemotaxis of human peripheral blood eosinophils to 2-arachidonoylglycerol: comparison with other eosinophil chemoattractants. Int Arch Allergy Immunol 2006; 140:3-7.
106. Oka S, Wakui J, Ikeda S, Yanagimoto S, Kishimoto S, Gokoh M, Nasui M, Sugiura T. Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachido-noylglycerol in oxazolone-induced contact dermatitis in mice. J Immunol 2006; 177:8796-805.
107. Larose MC, Turcotte C, Chouinard F, Ferland C, Martin C, Provost V, Laviolette M, Flamand N. Mechanisms of human eosinophil migration induced by the combination of IL-5 and the endocannabinoid 2-arachidonoyl-glycerol. J Allergy Clin Immunol 2014; 133: 1480-1482.
108. Facci L, Dal Toso R, Romanello S, Buriani A, Skaper SD, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 1995; 92:3376-80.
109. Wang J, Zheng J, Kulkarni A, Wang W, Garg S, Prather PL, Hauer-Jensen M. Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent manner. Dig Dis Sci 2014; 59:2693-703.
110. De Filippis D, Negro L, Vaia M, Cinelli MP, Iuvone T. New insights in mast cell modulation by palmitoylethanolamide. CNS Neurol Disord Drug Targets 2013; 12:78-83.
111. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARc receptors and neurotrophic factors. Pain 2008; 139:541-50.
112. Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav Immun 2011; 25:1099-112.
113. Bettoni I, Comelli F, Colombo A, Bonfanti P, Costa B. Non-neuronal cell modulation relieves neuropathic pain: efficacy of the endogenous lipid palmitoylethanolamide. CNS Neurol Disord Drug Targets 2013; 12:34-44.
114. Maccarrone M, Bari M, Battista N, Finazzi-Agro A. Endocannabinoid degradation, endotoxic shock and inflammation. Curr Drug Targets Inflamm Allergy 2002; 1:53-63.
115. Sugawara K, Bıro T, Tsuruta D et al. Endocannabinoids limit excessive mast cell maturation and activation in human skin. J Allergy Clin Immunol 2012; 129:726-38.e8.
116. Sugawara K, Zakany N, Hundt T et al. Cannabinoid receptor 1 controls human mucosal-type mast cell degranulation and maturation in situ. J Allergy Clin Immunol 2013; 132:182-93.
117. Jackson AR, Hegde VL, Nagarkatti PS, Nagarkatti M. Characterization of endocannabinoid-mediated induction of myeloid-derived suppressor cells involving mast cells and MCP-1. J Leukoc Biol 2014; 95:609-19.
118. Bluestone JA, Mackay CR, O’Shea JJ, Stockinger B. The functional plasticity of T cell subsets. Nat Rev Immunol 2009; 9:811-6.
119. Schwarz H, Blanco FJ, Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 1994; 55:107-15.
120. Jackson AR, Nagarkatti P, Nagarkatti M. Anandamide attenuates Th-17 cell-mediated delayed-type hypersensitivity response by triggering IL-10 production and consequent microRNA induction. PLoS ONE 2014; 9:e93954.
121. Sancho R, Calzado MA, Di Marzo V, Appendino G, Munoz E. Anandamide inhibits nuclear factor-jB activation through a cannabinoid receptor-independent pathway. Mol Pharmacol 2003; 63:429-38.
122. Rockwell CE, Raman P, Kaplan BL, Kaminski NE. A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated Jurkat T cells. Biochem Pharmacol 2008; 76:353-61.
123. Joseph J, Niggemann B, Zaenker KS, Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 2004; 53:723-8.
124. Malfitano AM, Matarese G, Pisanti S et al. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. J Neuroimmunol 2006; 171:110-9.
125. Chiurchiu V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, Maccarrone M. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 2010; 5:e8688.
126. Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agro A. Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. J Immunol 2001; 166:7183-9.
127. Lissoni P, Tintori A, Fumagalli L et al. The endocannabinoid anandamide neither impairs in vitro T-cell function nor induces regulatory T-cell generation. Anticancer Res 2008; 28:3743-8.
128. Sipe JC, Arbour N, Gerber A, Beutler E. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J Leukoc Biol 2005; 78:231-8.
129. Ziring D, Wei B, Velazquez P, Schrage M, Buckley NE, Braun J. Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics 2006; 58:714-25.
130. Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor c independently of cannabinoid receptors 1 and 2. Mol Pharmacol 2006; 70:101-11.
131. Pieper K, Grimbacher B, Eibel H. B-cell biology and development. J Allergy Clin Immunol 2013; 131:959-71.
132. Sherwood TA, Nong L, Agudelo M, Newton C, Widen R, Klein TW. Identification of transcription start sites and preferential expression of select CB2 transcripts in mouse and human B lymphocytes. J Neuroimmune Pharmacol 2009; 4:476–88.
133. Carayon P, Marchand J, Dussossoy D et al. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 1998; 92:3605–15.
134. Pereira JP, An J, Xu Y, Huang Y, Cyster JG. Cannabinoid receptor 2 mediates the retention of immature B cells in bone marrow sinusoids. Nat Immunol 2009; 10:403–11.
135. Muppidi JR, Arnon TI, Bronevetsky Y, Veerapen N, Tanaka M, Besra GS, Cyster JG. Cannabinoid receptor 2 positions and retains marginal zone B cells within the splenic marginal zone. J Exp Med 2011; 208:1941–8.
136. Agudelo M, Newton C, Widen R, Sherwood T, Nong L, Friedman H, Klein TW. Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes. J Neuroimmune Pharmacol 2008; 3:35–42.
137. Tanikawa T, Kurohane K, Imai Y. Induction of preferential chemotaxis of unstimulated B-lymphocytes by 2-arachidonoylglycerol in immunized mice. Microbiol Immunol 2007; 51:1013–9.